Other ·Emerging evidence ·Reviewed May 2026
Compound from cruciferous vegetables studied for estrogen metabolite patterns. It is not a stand-alone hormone therapy and has important drug-interaction and hormone-sensitive cancer cautions.
The bottom line
Evidence rating emerging. Most-documented uses: estrogen metabolism support (limited), hormonal acne support (limited), prostate biomarker support (early clinical). 21 sources indexed (1998–2025), with 8 interaction records on file.
Core mechanism
May shift estrogen metabolite patterns toward 2-hydroxy pathways, but also induces CYP1A2, CYP3A4, and MDR1 through AhR and PXR signaling. Low physiologic concentrations activated ERalpha in breast cancer cells in vitro, so hormone-sensitive use requires clinician guidance.10,1
Ranked by evidence and value.
Real-world pricing across three quality tiers. Assumes Microencapsulated DIM.
Assumes 100-200 mg/day. Vendor basis: NOW/iHerb, Vitacost, Pure Encapsulations, and Amazon marketplace; BioResponse DIM-style products cost more. Updated 2026-05-28.
How much you'd eat to match a supplemental dose.
Cruciferous vegetables provide indole-3-carbinol precursors; actual DIM formation varies.
What to test, the optimal window inside the conventional range, and how long a response takes.
Diindolylmethane (100 to 300 mg per day) raises urinary 2-OH estrone and the 2/16 ratio in 4- to 8-week RCTs.10,3
Specialty lab (DUTCH test or similar). Best as morning first-void or 24-hour collection. Cohort evidence linking ratio to clinical outcomes is mixed.
Where this appears in the symptom-to-supplement map, ranked by relevance.
Diindolylmethane may shift estrogen metabolism toward the 2-hydroxy pathway, which is hypothesized to favor a more balanced metabolite profile.1,6
Take with food for absorption; a harmless temporary darkening of urine can occur.
Diindolylmethane influences estrogen metabolite balance toward less proliferative pathways in early research, but clinical endometriosis evidence is lacking.3,10
Hormonally active, so coordinate with your clinician if you use hormonal contraception or therapy.
DIM shifts estrogen metabolism toward the 2-hydroxylation pathway, modestly relevant in estrogen-dominant heavy bleeding patterns.1,3
Requires gynecologic workup; not a substitute for evaluation of structural causes.
DIM may reduce androgenic acne by shifting estrogen metabolism and modulating androgen activity in some women.1,6
Most relevant for hormonal acne patterns (jawline, premenstrual flares).
DIM (diindolylmethane) influences estrogen metabolism, which is sometimes targeted in estrogen-dominant irregularity, though clinical data are preliminary.1,2
Discuss with a clinician before use if you take hormonal contraception or have a hormone-sensitive condition.
Diindolylmethane may shift estrogen metabolism toward less proliferative metabolites in early research, relevant to the estrogen-sensitivity of fibroids but unproven clinically.1,3
Hormonally active; coordinate with your clinician, particularly alongside hormonal medications.
Evidence-based stacks that include it, with the exact dose and timing each one uses.
DIM (a compound formed from cruciferous vegetables) can shift estrogen metabolite ratios and is used to support hormonally driven, premenstrual acne. Direct acne evidence is sparse and emerging, so treat it as an optional adjunct rather than a core therapy.16,17
DIM decreases endoxifen (tamoxifen's active metabolite) levels through CYP enzyme induction, potentially reducing tamoxifen's cancer-preventive benefit.
Recommendation: Do NOT combine without oncologist approval. DIM may reduce tamoxifen effectiveness.
Both are cruciferous-derived compounds that favorably shift estrogen metabolism and induce phase I and phase II detoxification, giving complementary support to hormone metabolism pathways.
Recommendation: Reasonable to combine for estrogen metabolism or detoxification goals. No timing separation is required.
DIM shifts estrogen metabolism toward 2-hydroxylation by inducing CYP1A enzymes, while milk thistle silymarin can mildly inhibit some CYP and glucuronidation enzymes, so co-use may modestly alter estrogen handling and the clearance of other liver-metabolized compounds.
Recommendation: Generally usable together, but be aware milk thistle may modestly modulate the enzymes DIM acts on. If also taking hormone therapy or narrow-margin CYP-metabolized medications, consult a clinician before combining.
DIM is a documented CYP1A2 inducer (shown in cultured human liver slices via the AhR pathway), and melatonin is primarily metabolized by CYP1A2. Regular DIM use can speed melatonin breakdown, potentially blunting the sleep-onset effect of an exogenous melatonin dose. Because this is an enzyme-induction effect that builds over days, simply spacing the two doses apart does not resolve it: induction is a systemic, sustained change in metabolism rather than a moment-of-contact conflict.
Recommendation: If you take DIM daily and use melatonin for sleep, do not expect dose separation to fix reduced melatonin effect: the issue is faster clearance, not timing of contact. If your usual melatonin dose (commonly 0.5 to 3 mg at night) seems less effective after starting daily DIM, discuss a modest dose adjustment with a clinician rather than escalating on your own. Allow 1 to 2 weeks after starting or stopping DIM for the metabolic effect to stabilize before judging melatonin's effect.
DHEA and DIM are frequently co-stacked for hormone balance, and the rationale is real: DHEA can raise androgen and estrogen levels (especially at higher doses or in older adults), while DIM steers estrogen toward the 2-hydroxylation clearance pathway. The convergence is genuine but the combined hormonal outcome depends heavily on individual aromatase activity, sex, menopausal status, and doses used. In some people DIM may partially offset DHEA-driven estrogen rises; in others the interaction simply makes overall estrogen and androgen levels harder to interpret.
Recommendation: Treat this combination as something to monitor rather than assume balances out. If using both, start each at a conservative dose (DHEA is commonly 25 to 50 mg/day; higher doses raise estrogen conversion substantially) and have a clinician check estradiol, testosterone, and DHEA-S after several weeks, especially for anyone with hormone-sensitive conditions or a history of hormone-related cancer. Do not stack them empirically to control estrogen without lab confirmation. No specific dose-timing separation is needed; the relevant control is total daily dosing plus monitoring.
DIM (diindolylmethane) modifies estrogen metabolism by activating CYP1A1 and CYP1A2 enzymes, shifting estrogen metabolism toward the 2-hydroxyestrone pathway (considered less potent). In men on testosterone replacement therapy (TRT), DIM is often used to manage estrogen elevations from aromatization. However, clinical evidence shows DIM can reduce both estradiol and testosterone levels. A year-long trial showed ~36% estradiol reduction and decreased testosterone, suggesting effects beyond simple estrogen metabolism modulation.
Recommendation: If using DIM on TRT, monitor both estradiol and total/free testosterone levels regularly. DIM may reduce estrogen as desired but could also lower testosterone levels. Discuss DIM use with your prescriber before starting. Prescription aromatase inhibitors may be more predictable if estrogen management is needed.
DIM (diindolylmethane) may affect thyroid hormone metabolism by inducing phase II conjugation enzymes. It can alter the estrogen-thyroid axis interaction and may increase levothyroxine clearance in some individuals.
Recommendation: Monitor TSH levels when starting DIM supplementation on levothyroxine. Dose adjustment may be needed. Take DIM at least 4 hours after levothyroxine.
DIM shifts estrogen metabolism toward 2-hydroxy metabolites (less potent), potentially reducing estradiol's effectiveness for menopausal symptom control.
Recommendation: If using DIM with estradiol HRT, monitor symptom control. DIM may reduce estradiol effectiveness. Discuss with your prescriber.
Numbered references. Citations throughout the page link here.
DIM supplementation favored the benign estrogen metabolism pathway (2-hydroxy) and was associated with decreased body fat in premenopausal women.
DIM supplementation for 12 months showed a trend toward reduced mammographic breast density in healthy BRCA carriers, suggesting potential chemopreventive effects.
BR-DIM improved estrogen metabolite ratios and SHBG but significantly reduced plasma tamoxifen metabolites including endoxifen, requiring oncologist oversight in tamoxifen users.
Gee JR, Saltzstein DR, Messing E et al.. Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP). 2016
Ashrafian L, Sukhikh G, Kiselev V et al.. Double-blind randomized placebo-controlled multicenter clinical trial (phase IIa) on diindolylmethane's efficacy and safety in the treatment of CIN: implications for cervical cancer prevention. The EPMA journal. 2015
The 2-hydroxyestrone:16-hydroxyestrone ratio increased significantly in patients taking DIM.
BR-DIM was well tolerated with minimal toxicity; 93% of patients had detectable prostatic DIM levels with inhibitory effects on AR and PSA observed.
DIM-treated subjects showed significant increases in 2-hydroxyestrone and a 47% increase in the 2-OHE1/16alpha-OHE1 ratio (favorable estrogen metabolite).
Srikanth Y, Reddy DH, Anusha VL et al.. Unveiling the Multifaceted Pharmacological Actions of Indole-3-Carbinol and Diindolylmethane: A Comprehensive Review. Plants (Basel, Switzerland). 2025
Harakeh S, Akefe IO, Saber SH et al.. Nanoformulated 3'-diindolylmethane modulates apoptosis, migration, and angiogenesis in breast cancer cells. Heliyon. 2024
Li W, Chang X, Zhou H et al.. Investigating the Inhibition of Diindolylmethane Derivatives on SARS-CoV-2 Main Protease. Journal of molecular recognition : JMR. 2024
Kour P, Saha P, Bhattacharya S et al.. Design, synthesis, and biological evaluation of 3,3'-diindolylmethane N-linked glycoconjugate as a leishmanial topoisomerase IB inhibitor with reduced cytotoxicity. RSC medicinal chemistry. 2023
Limited evidence of clinically relevant activity of DIM and limited long-term safety data; more clinical trials with DIM than with I3C are still needed.
DIM induced CYP3A4 and MDR1 expression at physiologically relevant concentrations, supporting drug-interaction cautions.
Physiologically obtainable DIM concentrations activated ERalpha signaling and increased proliferation in ER-positive breast cancer cell lines without estradiol.
Human liver slice work found DIM induced CYP1A enzymes, supporting medication interaction cautions.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack